Traveler's Disease Vaccine in Trials


GAITHERSBURG, Md - Officials at Antex Biolgics Inc., have announced they will being testing their Activax combination vaccine. Activax reportedly is designed to protect those inoculated from Campylobacter jejuni and Shigella sonnei.

Campylobacter jejuni is estimated to cause 400-500 million causes of diarrhea worldwide annually. The bacterium is found in contaminated food and water. Shigella also causes an additional 200 million cases each year and frequently causes endemic or epidemic dysentery.

Consumption of contaminated food and water are the most prevalent causes of traveler's disease. Symptoms include: gastritis, acute diarrhea, high fever, dehydration, severe dysentery and death.

Patient enrollment at the Naval medical Research Center at the Walter Reed Army Institute of medical Research in Forest Glen, Maryland begins this week.

Related Videos
Andrea Flinchum, 2024 president of the Certification Board of Infection Control and Epidemiology, Inc (CBIC) explains the AL-CIP Certification at APIC24
Association for Professionals in Infection Control and Epidemiology  (Image credit: APIC)
Lila Price, CRCST, CER, CHL, the interim manager for HealthTrust Workforce Solutions; and Dannie O. Smith III, BSc, CSPDT, CRCST, CHL, CIS, CER, founder of Surgicaltrey, LLC, and a central processing educator for Valley Health System
Jill Holdsworth, MS, CIC, FAPIC, CRCST, NREMT, CHL
Jill Holdsworth, MS, CIC, FAPIC, CRCSR, NREMT, CHL, and Katie Belski, BSHCA, CRCST, CHL, CIS
Baby visiting a pediatric facility  (Adobe Stock 448959249 by
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Related Content